Document is current
Any future updates will be listed below
-
Authors
Siemionow, Maria https://orcid.org/0000-0001-6372-6122
Cwykiel, Joanna
Heydemann, Ahlke
Garcia, Jesus
Marchese, Enza
Siemionow, Krzysztof
Szilagyi, Erzsebet
-
Funding
Funding for this research was provided by:
University of Illinois Chancellor’s Innovation Fund (CIF) Proof of Concept Award.
- License Information
-
More Information
Article History
First Online: 15 March 2018
Compliance with Ethical Standards
:
: KS is CEO and shareholder of Dystrogen Therapeutics SA, the company holds a license for DEC Therapy. MS is CMO and shareholder of Dystrogen Therapeutics SA, the company holds a license for DEC Therapy. The authors declare a potential conflict of interest. M.S. is the inventor on the patent application filed by University of Illinois at Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO/2016/201182). The authors JC, AH, JG, EM and ES have no financial conflict of interest.
: University of Illinois at Chicago has approved the Nepotism Disclosure and Management Plan for MS and KS. The authors JC, AH, JG, EM and ES do not have any non-financial conflict of interest.
